去纤维钠（去纤苷）进入医保了吗？

(Defibrinoside) is a multi-component biochemical complex developed by Gentium SpA in Italy. It is produced from pig small intestinal mucosal genomic DNA through controlled depolymerization. The chemical essence of the drug is a mixture of single-stranded deoxyoligonucleotide sodium salts with a molecular weight concentrated in the range of 15-30 kDa, with a purine-pyrimidine ratio greater than 0.85.

In foreign countries, defibrinated sodium has been on the market for many years, but it has not yet been approved for domestic marketing, and it has not been included in medical insurance. This means that currently, patients can only choose to purchase drugs overseas for use. In foreign countries, the price of defibrinated sodium is 21,600$/box, and the specification is 200mg/box. Since its price will also change due to exchange rate fluctuations, patients who want to know more about its specific price or want to purchase this drug can consult with the domestic professional and formal overseas medical service organization Medical Companion Travel.

Studies have shown that defibrinated sodium exerts various biological functions mainly by affecting vascular endothelial cell response and platelet activity. Defibrinated sodium contains nucleic acid aptamers that interact with adenosine A1 and A2 receptors, thereby reducing the response of endothelial cells to injury and protecting vascular endothelium. In vitro experiments and in vivo animal experiments have confirmed that defibrinated sodium can stimulate the release of prostacyclin PGl2. PGl2 is mainly synthesized and secreted by vascular endothelium and platelets. It dilates blood vessels and inhibits platelet aggregation by increasing the level of cAMP.

The increase in PGl2 can also inhibit the lipoxygenase pathway to reduce the production of leukotriene LTB4 and reduce ischemic tissue damage. Compared with large blood vessels, (Defitelio) a series of biological activities are mainly produced for small blood vessels. The profibrinolytic and anticoagulant activities are thought to be produced by increasing the expression of plasminogen activator tPA in vascular endothelial tissue while reducing the secretion of inhibitory factors PAI and tissue factor TF.

Recommended hot articles: /newsDetail/78594.html